Effects of Pulmonary Rehabilitation on Respiratory Function and Thickness of the Diaphragm in Patients with Post-COVID-19 Syndrome: A Randomized Clinical Trial.

Effects of Pulmonary Rehabilitation on Respiratory Function and Thickness of the Diaphragm in Patients with Post-COVID-19 Syndrome: A Randomized Clinical Trial.

Publication date: Jan 12, 2024

Rehabilitation is an effective method for improving the overall health of patients who have experienced the long-term effects of COVID-19. The double-blind, randomized prospective study assessed the effectiveness of a 6-week rehabilitation program among post-COVID-19 patients. A total of 59 patients under treatment following COVID-19 were randomly divided into two groups. Both groups completed the same six-week comprehensive exercise training program supported by a respiratory muscle trainer (Threshold IMT) during out-patient sessions. The control group performed placebo IMT. Respiratory muscle strength, chest wall expansion, spirometry, and diaphragm ultrasonography measurements were taken before and after the six weeks. The applied rehabilitation program improved respiratory muscle strength in both the study and control groups (p < 0. 001). There was a significant chest circumference increase in the study group (p < 0. 001). Spirometric parameters improved in both groups, with the study group showing a greater improvement: 8. 02% in FEV1 (p < 0. 001), 13. 24% in FVC EX (p < 0. 001) and 9. 67% in PEF (p < 0. 001). Rehabilitation also increased diaphragm thickness during maximum inhalation in both groups. Based on the study findings, the specialized outpatient rehabilitation program developed for post-COVID-19 patients has proven to be effective and safe.

Open Access PDF

Concepts Keywords
Maximum COVID-19
Outpatient long COVID-19
Pulmonary post-COVID-19
Randomized pulmonary rehabilitation
Trainer respiratory muscles training

Semantics

Type Source Name
disease MESH COVID-19
disease MESH Syndrome
disease VO effective
disease VO effectiveness
drug DRUGBANK Coenzyme M
disease MESH long COVID
disease MESH infection
disease VO Betacoronavirus
disease MESH severe acute respiratory syndrome
disease VO organization
disease MESH lymphopenia
drug DRUGBANK Isoxaflutole
disease IDO process
disease IDO symptom
disease IDO immunosuppression
disease MESH fibrosis
disease VO efficiency
disease VO frequency
disease VO protocol
disease IDO history
disease MESH complications
disease MESH Functional Status
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH deep vein thrombosis
disease MESH cancer
disease MESH demyelinating diseases
disease MESH contraindications
disease VO device
disease IDO intervention
drug DRUGBANK Etoperidone
drug DRUGBANK Cysteamine
drug DRUGBANK Water
drug DRUGBANK Bentiromide
disease VO volume
disease MESH respiratory infections
disease MESH muscle strength

Original Article

(Visited 1 times, 1 visits today)